Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Share:
Related CERN
Cerner Trading Lower; CEO Confirms Ongoing Cancer Treatment
Worst Performing Industries For November 4, 2015
26 Best Stocks For Value Investors This Week - 2/6/16 (Seeking Alpha)
Related ABCO
Benzinga's Top Initiations
New Survey Gives J.P. Morgan Confidence To Go Overweight Athenahealth, Allscripts & Advisory Board

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Jan 2016RBC CapitalUpgradesOutperformTop Pick
Nov 2015Deutsche BankMaintainsBuy
Nov 2015Stifel NicolausMaintainsSell

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters